Simple Summary Immune checkpoint inhibitors (ICIs) are a type of immunotherapy used to
treat a variety of cancers by helping a patient's own immune system to kill cancer cells. ICIs …

Immune checkpoint inhibitors have unique toxicities and response kinetics compared with
cytotoxic and gene-targeted anticancer agents. We investigated the impact of …

Simple Summary Immune checkpoint inhibitors (ICIs) are increasingly used for advanced
lung cancer, but few studies have reported on patient-reported outcomes (PROs) outside the …

PURPOSE Increasingly broad patient groups are being treated with immune checkpoint
inhibitors (ICIs) in clinical practice, but few studies have assessed their usage and outcomes …

In 1994, Rosenberg et al 1 published the first large prospective series of high-dose
interleukin-2 in refractory melanoma and renal cell cancers and observed infrequent but …

Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1, programmed cell
death ligand 1, and cytotoxic T lymphocyte-associated antigen-4 have shown significantly …

Immune checkpoint inhibitors (ICI) have demonstrated meaningful patterns of clinical
efficacy across various cancers. During their development, novel regulatory strategies and …

Background We describe the clinical benefit of immune checkpoint inhibitors using the
European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) …

Background As indications for immune checkpoint inhibitor (ICI) therapy have increased in
recent years, so has the proportion of patients eligible for this type of therapy. However, a …

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, improving
outcomes in patients with advanced malignancies. The use of ICIs in clinical practice, and …